The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
Open accessAbstract
BACKGROUND: The use of n-3 fatty acids may prevent cardiovascular events in patients with recent myocardial infarction or heart failure. Their effects in patients with (or at risk for) type 2 diabetes mellitus are unknown. METHODS: In this double-blind study with a 2-by-2 factorial design, we randomly assigned 12,536 patients who were at high risk for cardiovascular events and had impaired fasting glucose, impaired glucose tolerance, or diabetes to receive a 1-g capsule containing at least 900 mg (90% or more) of ethyl esters of n-3 fatty acids or placebo daily and to receive either insulin glargine or standard care. The primary outcome was death from cardiovascular causes. The results of the comparison between n-3 fatty acids and placebo are reported here. RESULTS: During a median follow up of 6.2 years, the incidence of the primary outcome was not significantly decreased among patients receiving n-3 fatty acids, as compared with those receiving placebo (574 patients [9.1%] vs. 581 patients [9.3%]; hazard ratio, 0.98; 95% confidence interval [CI], 0.87 to 1.10; P=0.72). The use of n-3 fatty acids also had no significant effect on the rates of major vascular events (1034 patients [16.5%] vs. 1017 patients [16.3%]; hazard ratio, 1.01; 95% CI, 0.93 to 1.10; P=0.81), death from any cause (951 [15.1%] vs. 964 [15.4%]; hazard ratio, 0.98; 95% CI, 0.89 to 1.07; P=0.63), or death from arrhythmia (288 [4.6%] vs. 259 [4.1%]; hazard ratio, 1.10; 95% CI, 0.93 to 1.30; P=0.26). Triglyceride levels were reduced by 14.5 mg per deciliter (0.16 mmol per liter) more among patients receiving n-3 fatty acids than among those receiving placebo (P<0.001), without a significant effect on other lipids. Adverse effects were similar in the two groups. CONCLUSIONS: Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even among omega‐3 fatty acid studies, there are marked differences with respect to the relatively low doses of omega‐3 administered and the ratio of EPA to DHA.16, 17, 18, 19, 20, 21, 22, 23, 24”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the ORIGIN trial, which enrolled more than 12,000 patients with impaired fasting glucose and at high risk for cardiovascular events, the administration of 1 g/day of combined EPA + DHA (465 mg of EPA and 375 mg of DHA) had no impact on cardiovascular mortality [89].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [89]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, many previous 20 , 21 , 22 , 23 and recently completed clinical studies 24 , 25 showed that ω3 PUFA supplementation did not offer significant favorable impacts on cardiovascular events.”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“The STRENGTH, VITAL, ASCEND, ORIGIN, OMEGA, ALPHA-OMEGA, GISSI-HF and GISSI-P trials randomized patients to receive either a combination of EPA and DHA or placebo; yet only the GISSI trials noted a statistically significant effect on cardiovascular events and mortality [96–103].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [99]
The cited source says what the claim attributes to it.
In the citing paper
“but subsequent larger trials failed to replicate these findings. 8,9”
From Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (2020) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, the dosage used in OMEMI was about twice that used in comparable earlier trials 5, 7, 23, 30 , although considerably lower than the dosage used in REDUCE-IT 14 , and also in the STRENGTH trial 36 .”
From Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction (2021) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“A limitation to the study is the inclusion rate of 26 % of screened candidates, which is relatively low compared to other n-3 PUFA trials not targeting elderly patients 30-33 .”
From Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction (2021) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“Other more recent omega‐3 therapy outcome studies conducted in the presence of statins have been less encouraging, but these studies were characterized by evaluating nonhypertriglyceridemic patient populations (eg, TG <200 mg/dL) and administering low doses of long‐chain omega‐3 fatty acids (eg, eicosapentaenoic acid [EPA] and/or docosoahexaenoic acid [DHA]).19, 20, 21, 22, 23, 24”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“Our initial manuscript included Trials such as ORIGIN8, ASCEND9, Alpha Omega10, and JELIS5; among these trials, only one trial had IPE, and the rest of the trials had a combination of EPA and DHA, so our results were skewed as search strategy missed significant studies.”
From Cardiovascular outcomes and coronary artery disease prevention secondary to icosapent ethyl: a meta-analysis of randomized clinical trials (2024) · cites this paper as [8]
In the citing paper
“Data from studies on supplementation with n-3 fatty acids do not support recommending n-3 fatty acid supplements for secondary prevention of CVD in T2DM.86,87”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [86]
In the citing paper
“In the ORIGIN (Outcome Reduction With Initial Glargine Intervention) trial, 12 537 patients (mean age 63.5 years) at high CVD risk with impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or T2DM were randomized to insulin glargine titrated to a fasting blood glucose level of ≤5.3 mmol/L (≤95 mg/dL) or standard care.86 After a median follow-up of 6.2 years, the incidence of CV”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [86]
In the citing paper
“The JELIS study692) conducted in Japan found that the addition of EPA to statins showed a significant preventive effect on major cardiovascular events compared to statin monotherapy.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [692]
In the citing paper
“Evidence does not conclusively support recommending n-3 (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) supplements for all people with diabetes for the prevention or treatment of cardiovascular events (70,209,210).”
From 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes:Standards of Care in Diabetes—2023 (2023) · cites this paper as [210]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Lichtenstein, A. H., Appel, L. J., Brands, M., Carnethon, M., Daniels, S., Franch, H. A., Franklin, B., Kris-Etherton, P., Harris, W. S., Howard, B., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.176158 · Cited by 2,705
(1999) · PubMed · Cited by 2,062
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Self-citationGISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350
Fish and Omega-3 Fatty Acid Intake and Risk of Coronary Heart Disease in Women
Hu, F. B. (2002) · JAMA · doi:10.1001/jama.287.14.1815 · Cited by 1,018
n–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction
Kromhout, D., Giltay, E. J., & Geleijnse, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003603 · Cited by 936
n–3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored
Calder, P. C. (2004) · Clinical Science · doi:10.1042/cs20040119 · Cited by 571
Cardiovascular effects of marine omega-3 fatty acids
Saravanan, P., Davidson, N. C., Schmidt, E. B., & Calder, P. C. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60445-x · Cited by 513
Research works printed but not linked: 1
- Gerstein H, 2008, Am Heart J, 155, 26
Cited by
Sorted by citations
Items 401–500 of 933
Origin and therapy for hypertriglyceridaemia in type 2 diabetes
Pang, J., Chan, D. C., & Watts, G. F. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i2.165 · Cited by 24
Management of Dyslipidemias in the Presence of the Metabolic Syndrome or Type 2 Diabetes
Matikainen, N., & Taskinen, M. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0309-3 · Cited by 24
The Role of n-3 Fatty Acids in Cardiovascular Disease: Back to the Future
Perez-Martinez, P., Katsiki, N., & Mikhailidis, D. P. (2019) · Angiology · doi:10.1177/0003319719842005 · Cited by 24
Derosa, G., D’Angelo, A., & Maffioli, P. (2022) · Phytotherapy Research · doi:10.1002/ptr.7564 · Cited by 24
The multidimensional benefits of eicosapentaenoic acid: from heart health to inflammatory control
Nassar, M., Jaffery, A., Ibrahim, B., Baraka, B., & Abosheaishaa, H. M. (2023) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-023-00265-6 · Cited by 24
Amiano, P., Machón, M., Dorronsoro, M., Chirlaque, M. D., Barricarte, A., Sánchez, M., Navarro, C., Huerta, J. M., Molina‐Montes, E., Sánchez‐Cantalejo, E., et al. (2013) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2013.08.011 · Cited by 24
Dietary supplementation with Lovaza and krill oil shortens the life span of long-lived F1 mice
Spindler, S. R., Mote, P. L., & Flegal, J. M. (2014) · AGE · doi:10.1007/s11357-014-9659-7 · Cited by 24
Kavanagh, K., Flynn, D. M., Jenkins, K. A., Wilson, M. D., & Chilton, F. H. (2013) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2013.04.003 · Cited by 24
Fish oils, coronary heart disease, and the environment
Greene, J., Ashburn, S. M., Razzouk, L., & Smith, D. A. (2013) · American Journal of Public Health · doi:10.2105/ajph.2012.300959 · Cited by 23
AlSaleh, A. F. F., Maniou, Z., Lewis, F. J., Hall, W. L., Sanders, T. A. B., & O’Dell, S. D. (2014) · Journal of Nutrition · doi:10.3945/jn.113.185108 · Cited by 23
Yang, B., Tseng, P., Hu, X., Zeng, B., Chang, J. P., Liu, Y., Chu, W.-J., Zhang, S., Zhou, Z.-L., Chu, C., et al. (2022) · Progress in Lipid Research · doi:10.1016/j.plipres.2022.101196 · Cited by 23
Losurdo, P., Grillo, A., Panizon, E., Cappellari, G. G., Fabris, B., Bardelli, M., Biolo, G., Zanetti, M., & Carretta, R. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413500716 · Cited by 23
Dai, W., Zhang, Z., & Zhao, S. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0923-1 · Cited by 23
Cuevas, A. M., & Rodrigo Alonso, K. (2016) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2016.04.004 · Cited by 23
Boden, W. E., Baum, S. J., Toth, P. P., Fazio, S., & Bhatt, D. L. (2020) · Future Cardiology · doi:10.2217/fca-2020-0106 · Cited by 23
Harada, M., Yamakawa, T., Kashiwagi, R., Ohira, A., Sugiyama, M., Sugiura, Y., Kondo, Y., & Terauchi, Y. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255147 · Cited by 23
Yu, F., Qi, S., Ji, Y., Wang, X., Fang, S., & Cao, R. (2022) · Medicine · doi:10.1097/md.0000000000029556 · Cited by 23
Documenting the Global Burden of Cardiovascular Disease
Yusuf, S., & McKee, M. (2014) · Circulation · doi:10.1161/circulationaha.114.008302 · Cited by 23
Prescription omega-3 fatty acid products: Considerations for patients with diabetes mellitus
Avallone, L., Shaikh, A., Hassan, A., & Tajuddin, N. (2016) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s97036 · Cited by 22
Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease
Brinton, E. A. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.09.012 · Cited by 22
Genomics of hypertriglyceridemia
Tada, H., Takamura, M., & Kawashiri, M. (2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.12.005 · Cited by 22
Clinical significance of polyunsaturated fatty acids in the prevention of cardiovascular diseases
Kotlyarov, S. N., & Котлярова, А. А. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.998291 · Cited by 22
Caffrey, C., Leamy, A., O’Sullivan, E., Zabetakis, I., Lordan, R., & Nasopoulou, C. (2023) · Marine Drugs · doi:10.3390/md21110549 · Cited by 22
Fezeu, L., Laporte, F., Kesse‐Guyot, E., Andreeva, V. A., Blacher, J., Herçberg, S., & Galan, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092548 · Cited by 22
n−3 PUFAs in cardiovascular disease
Marchioli, R., & Levantesi, G. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.06.042 · Cited by 22
Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease
Brinton, E. A. (2015) · Cardiology Clinics · doi:10.1016/j.ccl.2015.02.007 · Cited by 22
Vetter, M. L., Amaro, A., & Volger, S. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.01.2734 · Cited by 22
Sekikawa, A. M., Doyle, M. F., & Kuller, L. H. (2015) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.03.001 · Cited by 22
Linoleate appears to protect against palmitate-induced inflammation in Huh7 cells
Maruyama, H., Takahashi, M. P., Sekimoto, T., Shimada, T., & Yokosuka, O. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-78 · Cited by 22
Marine-derived n-3 fatty acids therapy for stroke
Campano, C. G. A., MacLeod, M. J., Thiès, F., Aucott, L. S., & Macleod, M. R. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012815 · Cited by 22
Dietary α-linolenic acid increases the platelet count in ApoE−/− mice by reducing clearance
Stivala, S., Reiner, M. F., Lohmann, C., Lüscher, T. F., Matter, C. M., & Beer, J. H. (2013) · Blood · doi:10.1182/blood-2013-02-484741 · Cited by 21
Kodera, S., Morita, H., Kiyosue, A., Ando, J., & Komuro, I. (2018) · Circulation Journal · doi:10.1253/circj.cj-17-0995 · Cited by 21
Laing, B. B., Cavadino, A., Ellett, S., & Ferguson, L. R. (2020) · Nutrients · doi:10.3390/nu12041139 · Cited by 21
Ponte-Negretti, C. I., Wyss, F., Piskorz, D. L., Santos, R. D., Villar, R., Lorenzatti, A., López-Jaramillo, P. A., Toth, P. P., Amaro, A. J. J., Rodrigo, A. K., et al. (2021) · Archivos de cardiología de México · doi:10.24875/acm.21000005 · Cited by 21
Djoussé, L., Cook, N. R., Kim, E., Walter, J. N., Al-Ramady, O. T., Luttmann‐Gibson, H., Albert, C. M., Mora, S., Buring, J. E., Gaziano, J. M., et al. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2021.12.006 · Cited by 21
Bassuk, S. S., & Manson, J. E. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac172 · Cited by 21
Zheng, T., Zhao, J., Wang, Y., Liu, W., Wang, Z., Shang, Y., Zhang, W., Zhang, Y., & Zhong, M. (2013) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2013.11.025 · Cited by 21
Icosapent ethyl for the treatment of hypertriglyceridemia
Ballantyne, C. M., Braeckman, R. A., & Soni, P. N. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.798645 · Cited by 21
Phase 4 Studies in Heart Failure - What is Done and What is Needed?
Iyngkaran, P., Liew, D., McDonald, P., Thomas, M. C., Reid, C. M., Chew, D. P., & Hare, D. L. (2016) · Current Cardiology Reviews · doi:10.2174/1573403x12666160606121458 · Cited by 21
New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk
Graham, I. M., Shear, C. L., de Graeff, P., Boulton, C., Catapano, A. L., Stough, W. G., Carlsson, S. C., Backer, G. D., Emmerich, J., Greenfeder, S. A., et al. (2017) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvx031 · Cited by 21
AbuMweis, S. S., Omran, D. A., Al-Shami, I. K., & Jew, S. (2021) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2021.102662 · Cited by 21
Platelet Redox Balance in Diabetic Patients With Hypertension Improved by n-3 Fatty Acids
McDonald, D., O’Kane, F., McConville, M., Devine, A. B., & McVeigh, G. E. (2012) · Diabetes Care · doi:10.2337/dc12-0304 · Cited by 21
Ahn, J., Park, S. K., Park, T. S., Kim, J. H., Yun, E., Kim, S.-P., Lee, H. W., Oh, J., Choi, J. H., Cha, K. S., et al. (2016) · Korean Circulation Journal · doi:10.4070/kcj.2016.46.4.481 · Cited by 21
Kitagami, M., Yasuda, R., Toma, N., Shiba, M., Nampei, M., Yamamoto, Y., Nakatsuka, Y., Sakaida, H., & Suzuki, H. (2017) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2017.04.010 · Cited by 21
Methylene-bridge tryptophan fatty acylation regulates PI3K-AKT signaling and glucose uptake
Hu, S., He, X., Nie, J., Hou, J., Wu, J., Liu, X., Wei, Y., Tang, H., Sun, W.-X., Zhou, S.-X., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110509 · Cited by 20
Lipoprotection in cardiovascular diseases
Benkhoff, M., & Polzin, A. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108747 · Cited by 20
Hassan, A., Tajuddin, N. N., & Shaikh, A. (2014) · Cardiology and Therapy · doi:10.1007/s40119-014-0032-9 · Cited by 20
Ismail, T. A., Soliman, M. M., NASSAN, M. A., & Mohamed, D. I. (2015) · Journal of Food and Nutrition Research · doi:10.12691/jfnr-3-2-1 · Cited by 20
Schæbel, L. K., Vestergaard, H., Laurberg, P., Rathcke, C. N., & Andersen, S. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.03.022 · Cited by 20
Concerning the “repression” of ω -3 polyunsaturated fatty acids by adepts of evidence-based medicine
Torshin, I. Y., Громова, О. А., & Kobalava, Z. D. (2019) · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology · doi:10.17749/2070-4909.2019.12.2.91-114 · Cited by 20
Jin, J., Zhang, H., Cao, Y., Liu, H., Hua, Q., Li, Y., Zhang, Y., Guo, Y., Wu, N., Zhu, C., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01125-1 · Cited by 20
Hu, T., Zhang, W., Han, F., Zhao, R., Liu, L., & An, Z. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.903412 · Cited by 20
Glück, T., & Alter, P. J. (2016) · Vascular Pharmacology · doi:10.1016/j.vph.2016.03.007 · Cited by 20
Masana, L., Ibarretxe, D., Heras, M., Cabré, A., Ferré, R., Merino, J., Plana, N., & Girona, J. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.12.001 · Cited by 19
When cardiovascular medicines should be discontinued
Krychtiuk, K. A., Gersh, B. J., Washam, J. B., & Granger, C. B. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae302 · Cited by 19
Deng, A., Pattanaik, S., Bhattacharya, A., Yin, J., Ross, L., Liu, C., & Zhang, J. (2018) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2018.05.011 · Cited by 19
n-3 Fatty acids and risk for fatal coronary disease
Harris, W. S., & Zotor, F. B. (2019) · Proceedings of The Nutrition Society · doi:10.1017/s0029665118002902 · Cited by 19
Rijjal, D. A., Liu, Y., Lai, M., Song, Y., Danaei, Z., Wu, A., Mohan, H., Li, W., Schopfer, F. J., Dai, F. F., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102909 · Cited by 19
Health benefits of omega-3 fatty acids
Calder, P. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821391-9.00006-5 · Cited by 19
The future of n-3 polyunsaturated fatty acid therapy
Davidson, M. H., & Benes, L. B. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000353 · Cited by 18
Diabetic Cardiac Autonomic Neuropathy
Serhiyenko, V. A., & Serhiyenko, A. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_53 · Cited by 18
Yang, X. H., Tu, Q. M., Li, L., Guo, Y. P., Wang, N. S., & Jin, H. M. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117187 · Cited by 18
Werida, R. H., Ramzy, A., Ebrahim, Y. N., & Helmy, M. W. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01511-2 · Cited by 18
Fukuoka, Y., Nuruki, N., Amiya, S., Tofuku, K., Aosaki, S., & Tsubouchi, H. (2013) · Journal of Cardiology · doi:10.1016/j.jjcc.2013.08.005 · Cited by 18
The Role of Long-Chained Marine N-3 Polyunsaturated Fatty Acids in Cardiovascular Disease
Aarsetoey, H., Grundt, H., Nygaard, O. K., & Nilsen, D. W. T. (2012) · Cardiology Research and Practice · doi:10.1155/2012/303456 · Cited by 18
Triglycerides and Cardiovascular Outcomes—Can We REDUCE-IT ?
Pradhan, A. K., Bhandari, M., Vishwakarma, P., & Sethi, R. (2020) · International Journal of Angiology · doi:10.1055/s-0040-1701639 · Cited by 18
Macartney, M. J., Peoples, G. E., & McLennan, P. L. (2020) · Journal of Nutrition · doi:10.1093/jn/nxaa256 · Cited by 18
Feingold, K. R. (2017) · Europe PMC (PubMed Central) · Cited by 18
Dinu, M., Sofi, F., Lotti, S., Colombini, B., Mattioli, A. V., Catapano, A. L., Casula, M., Baragetti, A., Wong, N. D., Steg, P. G., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae184 · Cited by 17
Lee, Y. S., Park, J. W., Joo, M., Moon, S., Kim, K., & Kim, M. G. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01137-8 · Cited by 17
Nutraceuticals and Supplements in Management of Prediabetes and Diabetes
Derosa, G., D’Angelo, A., Angelini, F., Belli, L., Cicero, A. F. G., ROS, R. D., Pergola, G. D., Gaudio, G. V., Lupi, A., Sartore, G., et al. (2024) · Nutrients · doi:10.3390/nu17010014 · Cited by 17
Htun, P., Nee, J., Ploeckinger, U., Eder, K., Geisler, T., Gawaz, M., Bocksch, W., & Fateh‐Moghadam, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135930 · Cited by 17
Managing dyslipidaemia in type 2 diabetes mellitus
Szalat, A., Durst, R. Y., & Leitersdorf, E. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.05.004 · Cited by 17
Determination of fatty acid composition content in the herbal antidiabetic collections
Savych, A., Marchyshyn, S. М., & Basaraba, R. (2020) · Pharmacia · doi:10.3897/pharmacia.67.e51812 · Cited by 17
Fernández, M. L., Blomquist, S. A., Hallmark, B., & Chilton, F. H. (2021) · Nutrients · doi:10.3390/nu13072154 · Cited by 17
N-3 polyunsaturated fatty acids for cardiovascular risk
Goff, Z. D., & Nissen, S. E. (2022) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000962 · Cited by 17
Krill Oil for Cardiovascular Risk Prevention: Is it for Real?
Backes, J. M., & Howard, P. A. (2014) · Hospital Pharmacy · doi:10.1310/hpj4910-907 · Cited by 17
Nutraceuticals and coronary heart disease
García‐Ríos, A., Delgado‐Lista, J., Alcala-Diaz, J. F., López‐Miranda, J., & Pérez‐Martínez, P. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32836081a5 · Cited by 17
Statin Combination Therapy and Cardiovascular Risk Reduction
Toth, P. P., Farnier, M., Tomassini, J. E., Foody, J. M., & Tershakovec, A. M. (2016) · Future Cardiology · doi:10.2217/fca-2015-0011 · Cited by 17
Motoyama, S., Nagahara, Y., Sarai, M., Kawai, H., Miyajima, K., Sato, Y., Matsumoto, R., Takahashi, H., Naruse, H., Ishii, J., et al. (2021) · Circulation Journal · doi:10.1253/circj.cj-21-0615 · Cited by 17
Markozannes, G., Ntzani, E. E., Tsapas, A., Mantzoros, C. S., Tsiara, S., Xanthos, T., Karpettas, N., Patrikios, I., & Rizos, E. C. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.02.022 · Cited by 16
Lancaster, G. I., & Murphy, A. J. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100765 · Cited by 16
Brosolo, G., Porto, A. D., Marcante, S., Capilupi, F., Bertin, N., Vivarelli, C., Bulfone, L., Vacca, A., Catena, C., & Sechi, L. A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177107 · Cited by 16
Roles of Lipoxygenases in Cardiovascular Diseases
Liu, T., & Ai, D. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-025-10605-2 · Cited by 16
Atherogenic Dyslipidemia and Combination Pharmacotherapy in Diabetes: Recent Clinical Trials
Hamilton, S. J., & Watts, G. F. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.191 · Cited by 16
Omega-3 Fatty Acids and Coronary Artery Disease: More Questions Than Answers
Tadić, M., Sala, C., Grassi, G. M., Mancia, G., Taddei, S., Rottbauer, W., & Cuspidi, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112495 · Cited by 16
Sethi, A., Bajaj, A., Khosla, S., & Arora, R. R. (2014) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000048 · Cited by 16
Cardioprotective effects of omega 3 fatty acids: origin of the variability
Roy, J., & Guennec, J. L. (2016) · Journal of Muscle Research and Cell Motility · doi:10.1007/s10974-016-9459-z · Cited by 16
Saraswathi, V., Heineman, R. D., Alnouti, Y., Shivaswamy, V., & Desouza, C. V. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107494 · Cited by 16
Complications of Diabetes Mellitus
Brownlee, M., Aiello, L. P., Cooper, M. E., Vinik, A. I., Nesto, R. W., & Boulton, A. J. M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00033-x · Cited by 16
Evidence-Based Cardiovascular Risk Management in Diabetes
Mooradian, A. D. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00336-6 · Cited by 16
Takeda, Y., Sakuma, I., Hiramitsu, S., Okada, M., Ueda, S., & Sakurai, M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1094100 · Cited by 15
Xiao, Y., Chen, Y., Pietzner, A., Elbelt, U., Fan, Z., & Weylandt, K. H. (2024) · Nutrients · doi:10.3390/nu16111610 · Cited by 15
The Need for Combination Drug Therapies in Patients with Complex Dyslipidemia
Barnett, J. R., Viljoen, A., & Wierzbicki, A. S. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0391-1 · Cited by 15
Eide, I. A., Dahle, D. O., Svensson, M. H. S., Hartmann, A., Åsberg, A., Bjerve, K. S., Christensen, J., Schmidt, E. B., Lauritsen, M. E., Lund, K., et al. (2016) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2016.14 · Cited by 15
Hande, L. N., Thunhaug, H., Enebakk, T., Ludviksen, J. K., Pettersen, K., Hovland, A., & Lappegård, K. T. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.08.004 · Cited by 15
Bethel, M. A., Stevens, S. R., Buse, J. B., Choi, J., Gustavson, S. M., Iqbal, N., Lokhnygina, Y. V., Mentz, R. J., Patel, R. A., Öhman, P., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.043353 · Cited by 15
Hoang, T., & Kim, J. (2020) · Nutrients · doi:10.3390/nu12082218 · Cited by 15
The journey of omega-3 fatty acids in cardiovascular medicine
Ferrari, R., Censi, S., & Cimaglia, P. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa118 · Cited by 15
Huang, P., Cheng, H., Su, Y., Huang, M., Hsu, C., Hwang, S., Shin, S., & Chang, W. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13944 · Cited by 15
Metadata
- Authors
- The ORIGIN Trial Investigators
- Corresponding author
- The ORIGIN Trial Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-07-26
- Volume
- 367
- Issue
- 4
- Pages
- 309-318
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1560062315
- Semantic Scholar
- 00cc8344ced92b3c8921b97df8607e6b3032e111
- Cited by
- 929
- References
- 21
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 41 · 2023: 53 · 2022: 51 · 2021: 57 · 2020: 76 · 2019: 60 · 2018: 72 · 2017: 56 · 2016: 90 · 2015: 79 · 2014: 90 · 2013: 122 · 2012: 38
- FWCI
- 97.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Monash University Research Portal (Monash University) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- IRIS (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- omega-3 fatty acids, cardiovascular outcomes, type 2 diabetes, dysglycemia, impaired fasting glucose, impaired glucose tolerance, insulin glargine, cardiovascular mortality, major vascular events, triglycerides, serum lipids, cardiac arrhythmias, cardiovascular risk reduction, dietary supplementation, omega-3 fatty acid ethyl esters
- MeSH terms
- Insulin Glargine, Aged, Cardiovascular Diseases, Cholesterol, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Male, Middle Aged, Triglycerides, Fatty Acids, Omega-3, Incidence, Proportional Hazards Models, Treatment Failure, Glucose Intolerance, Insulin, Long-Acting, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
